Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Selegiline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 11/20 | 0.93 |
| ▸ | MAOA | P21397 | 8/20 | 0.93 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.93 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.93 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.93 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.93 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.93 |
| ▸ | SNCA | P37840 | 1/20 | 0.93 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.93 |
| ▸ | PKM | P14618 | 1/20 | 0.93 |
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.90 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | HTR2A | P28223 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Selegiline SCHEMBL7105217 | 1.00 | MAOB (0.93) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL1286950 | 0.97 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL74753 | 0.97 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL15867136 | 0.97 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL12248117 | 0.97 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL22232 | 0.97 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL5499736 | 0.97 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL41392 | 0.95 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL473659 | 0.95 | MAOB (1.00) | MAOBMAOACYP1A2ADRA2BADRA2C | |
| Selegiline SCHEMBL4611911 | 0.92 | MAOB (0.90) | MAOBMAOACYP1A2ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | disclosed |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | TERRAN BIOSCIENCES, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-10905672-B2 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | PHARNEXT (FR) | 2021-02-02 | — | — | US | disclosed |
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigacions Cientificas (CSIS) (ES) | 2020-12-24 | — | — | US | disclosed |
| EP-3750982-A1 | CELL CULTURE PLATE, METHOD FOR PREPARING THEREOF AND METHOD FOR DETECTING A SUBSTANCE | UPM-Kymmene Corporation (FI) | 2020-12-16 | — | — | EP | disclosed |
| US-10799499-B2 | Combinatorial therapies of neurological disorders | PHARNEXT (FR) | 2020-10-13 | — | — | US | disclosed |
| US-20190111054-A1 | NOVEL COMBINATORIAL THERAPIES OF NEUROLOGICAL DISORDERS | PHARNEXT (FR) | 2019-04-18 | — | — | US | disclosed |
| EP-3411025-A1 | NOVEL COMBINATORIAL THERAPIES OF NEUROLOGICAL DISORDERS | Pharnext (FR) | 2018-12-12 | — | — | EP | disclosed |
| CN-105153195-B | A kind of tricyclic pyrazole [1,5 d] [1,4] benzo oxygen azatropylidene ketone derivatives and preparation method thereof and purposes | 汤文建 | 2017-09-26 | — | — | CN | disclosed |
| EP-2021502-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | Oy Jurilab Ltd (FI) | 2009-02-11 | — | — | EP | disclosed |
| EP-1991212-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | Braincells, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| WO-2007128884-A1 | NOVEL GENES AND MARKERS IN TYPE 2 DIABETES AND OBESITY | OY JURILAB LTD (FI) | 2007-11-15 | — | — | WO | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20060287299-A1 | Combination therapy for dementia, depression and apathy | SHELDON LESLIE J | 2006-12-21 | — | — | US | disclosed |
| EP-1713486-A1 | COMBINATION THERAPY FOR DEMENTIA,DEPRESSION AND APATHY | Sheldon, Leslie James (CA) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005053703-A1 | COMBINATION THERAPY FOR DEMENTIA, DEPRESSION AND APATHY | SHELDON LESLIE JAMES (CA) | 2005-06-16 | — | — | WO | disclosed |
| US-20030212144-A1 | Method for inducing an estrous cycle and pregnancy in a female mammal | MOHANKUMAR, SHEBA M. J. | 2003-11-13 | — | — | US | disclosed |
| WO-2002005805-A1 | METHOD FOR INDUCING AN ESTROUS CYCLE AND PREGNANCY IN A FEMALE MAMMAL | MICHIGAN STATE UNIVERSITY (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | MAOB 53/4885MAOA 51/4885CYP1A2 828/4885 |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | MAOB 55/4885MAOA 48/4885CYP1A2 722/4885 |
| US-10905672-B2 | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders | CPT1B, APOB, GABRB3 | MAOB 277/4885MAOA 1271/4885CYP1A2 2729/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | MAOB 53/4885MAOA 51/4885CYP1A2 828/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | MAOB 699/4885MAOA 658/4885CYP1A2 4792/4885 |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | HTR2A, HTR2C, HTR1A | MAOB 53/4885MAOA 51/4885CYP1A2 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.